Depending on the cancer background setting, it has been shown that CHK1 inhibitors may either upregulate PD-L1 expression and then increase the response to anti-PD-L1 [121], or decrease PD-L1 expression after DSB [122]. This evidence concerns the gene CHEK1 and cancer.